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Ingredient Lot number 
starting material 
Concentration in Triple 
 IT sol (%m/V) 
Solu-medrol 
(methylprednisolone (21) 
sodium succinate) 
X06014 (Batch 1) 
0.0510 X06014 (Batch 2) 
X02490 (Batch 3) 
Emthexate 
(methotrexate) 
10A25LB (all) 0.1538 
Cytosar 
(cytarabine) 
EK74F (all) 0.385 
Objective: short-term stability evaluation of ex-tempore Triple IT solution (n=3) 
 
 
Storage conditions:  5 C / 50% relative humidity 
     25 C / 60% relative humidity (ICH storage rooms) 
     40 C / 75% relative humidity (ICH storage rooms) 
Packaging materials: Plastic syringes (PhaSeal® system) [Syr] 
     Brown glass vials with rubber stopper [Gl] 
     Brown glass vials with rubber stopper + metal needles [Gl+N] 
 
 
Methotrexate: stable 
Cytarabine: stable 
Methylprednisolone (21) sodium succinate: degradation 
Temperature  
 
Time  
 
Batch (B)??? 
Methylprednisolone 
Methylprednisolone (17)  sodium succinate 
Major degradation mechanism 
Evaluation of MP21SS batch-to-batch variability (= factor) on 
finished drug product (Triple IT) stability (= response)  
1 Evaluate finished product B3 k stability values with the k values of 
B1 and B2, set at 100% (identical MP(21)SS batch) 
2 Average difference between batch 3 and mean of both 1 + 2: 
 9.10% with 95% CI: [3.67% - 14.52%] 
 H0: average difference: 0  discarded 
Batch 3 is statistically significant more stable than batch 1 and 2 
The short-term (48 hrs.) storage stability of three batches triple intrathecal (Triple IT) solution under various conditions were evaluated. A statistically 
significant variability in methylprednisolone (21) sodium succinate degradation kinetics, linked to use of different batches Solu-Medrol®, was observed. This 
is a case where the stability of an in-situ ex-tempore prepared formulation is dependent on batch-to-batch quality variability of industrial drug products as 
starting material and further underlines the need of incorporating excipient / starting material quality in the Quality-by-Design approach in order to obtain 
consistent stability profiles.  
The use of poorly selected excipients in drug formulations can have a significant influence on the overall stability of the finished drug product. 
Therefore, evaluation of chemical and physical excipient compatibility with the active pharmaceutical ingredient (API) has become a major part in the 
development of new drug products. Moreover, while general and individual limits for excipient impurities have been set by the Ph. Eur. and USP, batch 
to batch variability of these excipient impurities, although still Ph. Eur. / USP compliant, can cause significant variability in the stability profile (= 
response) of a finished drug product.  Although currently often overlooked, the excipient quality (= factor) should be an important consideration of the 
Quality-by-Design (QbD) approach [1], as a consistent stability profile is a highly desired quality attribute, as recently demonstrated by β-artemether-
containing antimalarial products [2]. 
We demonstrated the influence of the quality of the starting materials, i.e. methylprednisolone (21) sodium succinate, on the variability in the stability 
profile of an in-situ ex-tempore prepared drug solution for intrathecal use (Triple IT), used in pedratric oncology [3]. 
Methylprednisolone (21)  sodium succinate 
